Shots:
- Solid Biosciences has entered into a non-exclusive global license & collaboration agreement with Kinea Bio to develop & commercialize KNA-155 for treating dysferlin-related limb-girdle muscular dystrophy, using Solid’s AAV-SLB101 capsid
- As per the deal, Kinea Bio will receive a non-exclusive global license to utilize AAV-SLB101 for the delivery of KNA-155, which will enter IND-enabling studies in exchange for an upfront fee as well as development & sales milestone payments, with net-sales based tiered royalties
- AAV-SLB101 has shown robust cardiac & skeletal muscle transduction, along with biodistribution in preclinical studies & ongoing P-I/II (INSPIRE DUCHENNE) trial evaluating SGT-003 (utilizes AAV-SLB101) for DMD
Ref: Solid Biosciences | Image: Solid Biosciences and Kinea Bio | Press Release
Related News:- Variational AI Collaborates with Merck to Develop Small Molecule Therapeutics
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
